$ News

Novartis completes acquisition of Tourmaline Bio

Novartis announces expiration of Tourmaline Bio tender offer

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer

Novartis announces commencement of tender offer to acquire Tourmaline Bio

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

Tourmaline Bio (TRML): Assessing Valuation as Market Interest Grows

Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense'

Novartis & Tourmaline, Anglo American & Teck, CoreWeave AI fund

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress

Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know

Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Here's Why We're Not Too Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Situation

Tourmaline Bio: We Should Wait For Upcoming Phase 2b Trial Data